Slide 1: Organic growth, strong cash flow and regulatory milestone
Organic growth, strong cash flow and regulatory milestone Getinge Q1 2026 Mattias Perjos, CEO Agneta Palmér, CFO
Slide 2: Key pillars for Getinge's profitable growth journey
Key pillars for Getinge’s profitable growth journey Development for strategic KPIs Increase share from recurring revenue Increase sales share from high margin products1 Less field actions per Bn SEK Net sales Capital goods Recurring revenue Rest of Portfolio High margin products -58% 1,9 1,2 1,0 66%
Slide 3: Key takeaways
Key takeaways Q1 2026 • Net sales grew by 0.8% organically and order intake increased by 3.9% organically • Margins in the quarter still heavily impacted by currency and tariffs – yet underlying solid improvement • Strong cashflow and financial position 38,000 53 16 36,000 34,092 52 15 34,000 51 50.
Slide 4: Key activities and events
Key activities and events Q1 2026 Offering and Customers Sustainability and Quality • Situation in the Middle East – First priority is our employees • CE approval for Cardiohelp II, the next generation of the and customers in the region. Limited impact on top line so far. transportable extracorporea
Slide 5: Cardiohelp II - The new flagship in the ECLS market
Cardiohelp II - The new flagship in the ECLS market Excellence. Advanced. Increased mobility Even easier Attachable gas to operate blender Strong clinical Decision support performance functionality Q1 2026 Q2 2026 Q3 2026 CE-mark approval for Limited Full CE-markets Cardiohelp II market release mark
Slide 6: Solid organic growth in Life Science and Surgical Workflows
Solid organic growth in Life Science and Surgical Workflows Order Intake and Net Sales Bridge Q1 2025 – Q1 2026 Order Intake Net Sales Organic Organic change -1.2% +2.9% +13.3% +3.9% change -4.0% +16.0% +4.0% +0.8% -8.0% 44 -10.5% -668 -70 -763 53 -167 SEK M SEK M 8,632 7,939 8,320 7,443 Q1 2025 Acu
Slide 7: Margins impacted by continued headwinds from currency and tariffs
Margins impacted by continued headwinds from currency and tariffs Adjusted Gross Profit and EBITA Bridge Q1 2025 – Q1 2026 Adjusted Gross Profit Adjusted EBITA Adj GM,% Margin development Q1 2026 60.2 37.6 42.7 51.4 +0.3 pp Adj GP (Q1 2025) (60.6) (39.4) (41.2) (52.1) -1.1 pp Adj OPEX +0.1 pp D&A -0
Slide 8: Getinge continues to have a solid financial position
Getinge continues to have a solid financial position Strong FCF in quarter and good safety margin on leverage FCF positively impacted by improved operating profit… … and leverage continues to be well below 2.5x 1.7 1.6 1.4 1.5 1.5 1.2 1.7 1.6 0.8 1.5 1.5 0.8 1.4 0.5 (1.1x excl. pension liabilities)
Slide 9: Tariffs and FX diluting underlying margin by -1.5 pp
Tariffs and FX diluting underlying margin by -1.5 pp Impact on margin from tariffs and FX Impact on adj EBITA in Q1 2026 Illustrative view on adj EBITA margin excl tariffs and FX in -226* Q1 2025 vs Q1 2026 12,6 12,5 MSEK 12,1 11,1 Q1 2025 Q1 2026 Reported adj EBITA margin Excl tariffs Excl FX and t
Slide 10: Steady traction towards the financial target in 2028
Steady traction towards the financial target in 2028 Main profitability drivers Capital Market Update in May 2024 Adj. EBITA Margin bridge 2023-2028 Main drivers for improved profitability 2026-2028 • Key strategic product launches and regulatory approvals in 2026-2027 ~16-19% Growth • US pharma inv
Slide 11: Net sales for 2026 expected to increase by 3-5% organically
Outlook 2026 Net sales for 2026 expected to increase by 3-5% organically* * Adjusted for the phase out of Surgical Perfusion, which is expected to have net sales in 2026 declining from about 250 MSEK to 50 MSEK Getinge │ Presentation │ Q1 Report 2026 April 21, 2026
Slide 12: Summary
Summary Getinge │ Presentation │ Q1 Report 2026 April 21, 2026
Slide 13: Key takeaways
Key takeaways Summary Q1 2026 • Organic growth in both order intake and sales • Margins still heavily impacted by currency and tariffs – yet solid underlying improvement • Strong cash flow and financial position • Outlook for 2026: organic net sales growth of 3-5%, adjusted for the phase out of Surg
Slide 14: Q&A
Q&A Getinge │ Presentation │ Q1 Report 2026 April 21, 2026
Slide 15: Thank you
Thank you Getinge │ Presentation │ Q1 Report 2026 April 21, 2026
Slide 16: Forward looking information
Forward looking information This document contains forward-looking information based on the current expectations of the Getinge’s management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectation
Slide 17: Getinge - Passion for Life
“~~ Se A GETINGE PASSION FOR LIFE